Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Heart disease prevention is moving earlier in life, with new cardiology guidelines urging cholesterol screening and treatment starting as young as 30.
Meanwhile, two more drugmakers are joining TrumpRx, ALS advocates warn funding cuts could slow research, and device makers are still waiting years for Medicare coverage after FDA approval.Continue to STAT+ to read the full story…